APA (7th ed.) Citation

Korotaeva, Т. V., Samtsov, A. V., Bakulev, A. L., Kokhan, M. M., Minullin, I. K., Vylegzhanina, O. A., . . . Ivanov, R. A. (2018). Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial. IMA-PRESS LLC.

Chicago Style (17th ed.) Citation

Korotaeva, Т. V., et al. Comparative Efficacy and Safety of Adalimumab Biosimilar (BCD-057) and Innovator in Patients with Psoriasis Vulgaris. Results of the BCD-057-2/CALYPSO Phase III International, Multicenter, Randomized Double-blind Clinical Trial. IMA-PRESS LLC, 2018.

MLA (9th ed.) Citation

Korotaeva, Т. V., et al. Comparative Efficacy and Safety of Adalimumab Biosimilar (BCD-057) and Innovator in Patients with Psoriasis Vulgaris. Results of the BCD-057-2/CALYPSO Phase III International, Multicenter, Randomized Double-blind Clinical Trial. IMA-PRESS LLC, 2018.